Do you want to read an article? Please log in or register.
Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma
Lymphoma
Related content
Lymphoma
Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study
Lancet Haematol
Rutherford SC, Abramson JS, Bartlett NL, Barta SK, Khan N, Joyce R, Maddocks K, Ali-Shaw T, Senese S, Yuan Y, Westin J, Leonard JP
doi: 10.1016/S2352-3026(21)00273-8
RECOMMENDED
Lymphoma
Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303
J Clin Oncol.
Bartlett NL, Wilson WH, Jung SH, Hsi ED, Maurer MJ, Pederson LD, Polley MC, Pitcher BN, Cheson BD, Kahl BS, Friedberg JW, Staudt LM, Wagner-Johnston ND, Blum KA, Abramson JS, Reddy NM, Winter JN, Chang JE, Gopal AK, Chadburn A, Mathew S, Fisher RI, Richards KL, Schöder H, Zelenetz AD, Leonard JP
doi: 10.1200/JCO.
Lymphoma
Dose-Adjusted Etoposide, Doxorubicin, and Cyclophosphamide With Vincristine and Prednisone Plus Rituximab Therapy in Children and Adolescents With Primary Mediastinal B-Cell Lymphoma: A Multicenter Phase II Trial
J Clin Oncol
Burke GAA, Minard-Colin V, Aupérin A, Alexander S, Pillon M, Delgado R, Zsíros J, Uyttebroeck A, Dartigues P, Miles RR, Kazanowska B, Chiang AK, Haouy S, Bollard CM, Csoka M, Wheatley K, Barkauskas DA, Adamson PC, Vassal G, Patte C, Gross TG
doi: 10.1200/JCO.21.00920
RECOMMENDED
Lymphoma
A dose-dense short-term therapy for human immunodeficiency virus/acquired immunodeficiency syndrome patients with high-risk Burkitt lymphoma or high-grade B-cell lymphoma: safety and efficacy results of the "CARMEN" phase II trial
Br J Haematol.
Ferreri AJM, Cattaneo C, Lleshi A, Verga L, Allione B, Facchetti F, Ponzoni M, Foppoli M, Ferrari D, Rigacci L, Pecciarini L, Donadoni G, Fumagalli L, Sassone M, Calimeri T, Rossi G, Spina M, Re A
doi: 10.1111/bjh.17188.Visit the original publication at ncbi.nlm.nih.gov
RECOMMENDED
Lymphoma
A dose-dense short-term therapy for human immunodeficiency virus/acquired immunodeficiency syndrome patients with high-risk Burkitt lymphoma or high-grade B-cell lymphoma: safety and efficacy results of the "CARMEN" phase II trial
★ 2
Recommended by
Alexander Meisel, Faculty Member
Br J Haematol
Ferreri AJM, Cattaneo C, Lleshi A, Verga L, Allione B, Facchetti F, Ponzoni M, Foppoli M, Ferrari D, Rigacci L, Pecciarini L, Donadoni G, Fumagalli L, Sassone M, Calimeri T, Rossi G, Spina M, Re A
doi: 10.1111/bjh.17188
Lymphoma
R-hyper-CVAD versus R-CHOP/cytarabine with high-dose therapy and autologous haematopoietic stem cell support in fit patients with mantle cell lymphoma: 20 years of single-center experience
Ann Hematol.
Widmer F, Balabanov S, Soldini D, Samaras P, Gerber B, Manz MG, Goede JS
doi: 10.1007/s00277-017-3180-x.
Lymphoma
Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study
Lancet Oncol.
Chiappella A, Martelli M, Angelucci E, Brusamolino E, Evangelista A, Carella AM, Stelitano C, Rossi G, Balzarotti M, Merli F, Gaidano G, Pavone V, Rigacci L, Zaja F, D'Arco A, Cascavilla N, Russo E, Castellino A, Gotti M, Congiu AG, Cabras MG, Tucci A, Agostinelli C, Ciccone G, Pileri SA, Vitolo U
doi: 10.1016/S1470-
RECOMMENDED
Gynecologic Cancer
Dose-Volume Effects and Risk Factors for Late Diarrhea in Cervix Cancer Patients after Radiochemotherapy with Image-Guided Adaptive Brachytherapy in the EMBRACE I Study
★ 1
Recommended by
Alexander Meisel, Faculty Member
Int J Radiat Oncol Biol Phys.
Kibsgaard Jensen NB, Pötter R, Spampinato S, Fokdal LU, Chargari C, Lindegaard JC, Schmid M, Sturdza A, Jürgenliemk-Schulz IM, Mahantshetty U, Segedin B, Bruheim K, Hoskin P, Rai B, Wiebe E, Cooper R, Van der Steen-Banasik E, Van Limbergen E, Sundset M, Pieters BR, Nout R, Kirisits C, Kirchheiner K, Tanderup K, EMBRACE Collaborative Group.
doi: 10.1016/j.ijrobp.2020.10.006.Visit the original publication at ncbi.nlm.nih.gov
Lymphoma
Dose-Adjusted Epoch and Rituximab for the treatment of double expressor and double hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome
Haematologica
Dodero A, Guidetti A, Marino F, Tucci A, Barretta F, Re A, Balzarotti M, Carniti C, Monfrini C, Chiappella A, Cabras A, Facchetti F, Pennisi M, Rahal D, Monti V, Devizzi L, Miceli R, Cocito F, Farina L, Ricci F, Rossi G, Carlo-Stella C, Corradini P
doi: 10.3324/haematol.2021.278638